Literature DB >> 26529923

[Pharmacology of bone resorption inhibitor].

Kunitaka Menuki, Akinori Sakai.   

Abstract

Currently, bone resorption inhibitor is mainly used for osteoporosis. A number of these agents have been developed. These pharmacological action are various. Bisphosphonate inhibit functions of the osteoclasts by inducing apoptosis. On the one hand, RANK-ligand inhibitor and selective estrogen receptor modulator inhibit formation of osteoclasts. It is important to understand these pharmacological action for the selection of the appropriate medicine.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26529923

Source DB:  PubMed          Journal:  Nihon Rinsho        ISSN: 0047-1852


  1 in total

1.  Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.

Authors:  H Qiao; T-y Wang; Z-f Yu; X-g Han; X-q Liu; Y-g Wang; Q-m Fan; A Qin; T-t Tang
Journal:  Cell Death Dis       Date:  2016-02-11       Impact factor: 8.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.